Navigation Links
Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
Date:2/3/2009

           - President of Bioniche Food Safety an invited speaker -

BELLEVILLE, ON, Feb. 3 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced that its President of Bioniche Food Safety, Rick Culbert, is today participating in a Canadian Beef Value Chain Roundtable in Gatineau, Quebec. The two-day Roundtable involves representatives from regulatory authorities, ranchers, feedlot operators, processors, retail and food service representatives, feed suppliers and others. They are meeting to develop a strategy focused on improving competitiveness of the Canadian beef industry through market access and development, the regulatory environment, research and innovation and information transfer.

In his presentation to the Roundtable, Mr. Culbert will be sharing information about the Company's Econiche(TM) cattle vaccine, the world's first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157. Econiche is fully licensed for sale in Canada by the Canadian Food Inspection Agency (CFIA).

The vaccine has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle and, in turn, reduce the risk to human health. An outbreak of human infection with E. coli O157 last fall in North Bay, Ontario, Canada involved 250 people reporting symptoms 50 lab-confirmed cases of human illness including one case of Haemolytic Uremic Syndrome (HUS). The illnesses were associated with a Harvey's Restaurant in that community.

Most strains of E. coli are harmless but some, like O157:H7, can cause severe illness and even be fatal when ingested by humans from contaminated meat, vegetables or water. Vaccination of cattle with Econiche can help reduce the risk of food and waterborne contamination with E. coli O157. Cows carry E. coli O157:H7 but they don't get sick. Where the disease comes from is people encountering contaminated food or water, usually from cow feces.

On-farm interventions to reduce the shedding of E. coli O157 by cattle, such as simple vaccination of cattle with Econiche, have the potential to reduce food and water contamination and the consequences associated with human infection with the deadly bacteria. Clinical trials conducted with Econiche have shown a significant reduction in the amount of E. coli shed in the manure of vaccinated cows.

"At today's Beef Value Chain Roundtable, I will be discussing the collaborative Canadian partnership that led to the development of Econiche," said Rick Culbert, President of Bioniche Food Safety. "I will also share information about the opportunity that vaccination of Canadian cattle represents beyond protecting public health, that is, a potential enhancement of the competitiveness of Canadian beef in export markets, where the vaccine is not yet available to producers."

About the Beef Value Chain Roundtable

The Beef Value Chain Roundtable was launched in January, 2003 and emerged as a key vehicle for helping ensure a coordinated response to Bovine Spongiform Encephalopathy (BSE) and as a key focal point for various working groups to engage with representatives of the entire beef value chain. Now more focused on long-term issues, membership on the beef roundtable includes ranchers, feedlot operators, processors, retail and food service representatives, feed suppliers and others.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
2. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
3. Bioniche Reports Fiscal 2009 First Quarter
4. Bioniche Allows Conversion of Portion of Revolving Credit Facility
5. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
6. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
7. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
8. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
9. Bioniche Presents Pre-Clinical Research at Two International Conferences
10. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
11. Bioniche Reports Fiscal 2008 Third Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is pleased to be invited to the Siemens Healthineers annual customer education symposium, ... The event will take place from March 27 - 31, 2017 at the ...
(Date:3/28/2017)... ... 28, 2017 , ... City trips have soared 82% since ... Report). As travelers visit both urban destinations, they are faced with exploration that ... In response, the outdoor industry has blurred the lines between fashion and function ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in the ... Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most affordable ... the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with the ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology: